Sanofi To Test Arthritis Drug Kevzara For Coronavirus
'Scientific Rationale' Behind Regeneron-partnered IL-6 Inhibitor
Executive Summary
The French giant is already working on a vaccine to combat COVID-19 and is now evaluating whether its rheumatoid arthritis drug Kevzara could treat pulmonary complications related to the coronavirus.
You may also be interested in...
Coronavirus Hasn’t Sparked CURE ID Physician Social Network Interest
US FDA/NIH smartphone app is intended to allow clinicians and others to talk about potential treatments for infectious diseases, but so far COVID-19-related activity has been limited.
India Coronavirus Actions: Stock Checks, Kaletra Gx Readiness And Bulk Drugs
A string of actions to ensure medicines security and prioritize bulk drug project clearances are underway in India as the country enters a critical phase in its efforts to contain coronavirus cases.
Sanofi And Regeneron Initiate 400-Patient Coronavirus Trial With Kevzara
The Phase II/III trial will begin enrolling patients in the US immediately, with Regeneron taking the lead in US development and Sanofi leading ex-US trials.